Karyopharm receives orphan drug designation from fda for eltanexor for the treatment of myelodysplastic syndromes

Newton, mass., jan. 24, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the u.s. food and drug administration (fda) has granted orphan drug designation for eltanexor, a novel oral, selective inhibitor of nuclear export (sine) compound, for the treatment of myelodysplastic syndromes (mds).
KPTI Ratings Summary
KPTI Quant Ranking